Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial

Diminished vasculogenesis under inflammatory conditions is mediated by Activin A

(2023) Sahana Manohar-Sindhu et al.   ANGIOGENESIS

Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension

(2023) Christophe Guignabert et al.   CIRCULATION

Right Ventricular Failure

(2023) Brian A. Houston et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

(2023) Marius M. Hoeper et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure

(2023) Sachindra R. Joshi et al.   Frontiers in Cardiovascular Medicine

How to incorporate tricuspid regurgitation in right ventricular-pulmonary arterial coupling

(2023) Keimei Yoshida et al.   JOURNAL OF APPLIED PHYSIOLOGY

Long-Term Effects of Sotatercept on Right Ventricular Function

(2023) Mardi Gomberg-Maitland et al.   JACC-Heart Failure

Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension

(2022) Sachindra R. Joshi et al.   Scientific Reports

Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis

(2022) Stephan Rosenkranz et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Sotatercept for the Treatment of Pulmonary Arterial Hypertension

(2021) Marc Humbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension

(2021) Gusty R. T. Ryanto et al.   Nature Communications

ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension

(2020) Lai-Ming Yung et al.   Science Translational Medicine

Targeting Transforming Growth Factor Beta Receptors in Pulmonary Hypertension

(2020) Christophe Guignabert et al.   EUROPEAN RESPIRATORY JOURNAL

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for use in Patients with Pulmonary Arterial Hypertension

(2020) Raymond L. Benza et al.   CHEST

Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension

(2018) Khodr Tello et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model

(2017) Marius M. Hoeper et al.   EUROPEAN RESPIRATORY JOURNAL

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension

(2017) Athénaïs Boucly et al.   EUROPEAN RESPIRATORY JOURNAL

RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction

(2017) Marco Guazzi et al.   JACC-Cardiovascular Imaging

Opposite effects of Activin type 2 receptor ligands on cardiomyocyte proliferation during development and repair

(2017) Deepika Dogra et al.   Nature Communications

Riociguat for the Treatment of Pulmonary Arterial Hypertension

(2013) Hossein-Ardeschir Ghofrani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

(2012) Gérald Simonneau et al.   EUROPEAN RESPIRATORY JOURNAL